Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan
International Journal of Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
29(8), P. 1088 - 1095
Published: July 2, 2024
Language: Английский
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma
International Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Language: Английский
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study
British Journal of Cancer,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 30, 2024
Language: Английский
Trends of minimally invasive surgery in the primary treatment of cervical cancer
Journal of Obstetrics and Gynaecology Research,
Journal Year:
2024,
Volume and Issue:
50(S1), P. 72 - 78
Published: Oct. 1, 2024
Abstract
Minimally
invasive
surgery
(MIS),
including
laparoscopic
and
robot‐assisted
procedures,
has
rapidly
advanced
in
the
treatment
of
gynecologic
malignancies
worldwide.
However,
its
adoption
insurance
coverage
AOFOG
countries
remain
limited,
particularly
for
uterine
ovarian
cancers.
This
limitation
poses
a
challenge
to
widespread
use
MIS,
highlighting
need
more
comprehensive
evaluation
role
skills
required
by
oncologists
ensure
safe
effective
treatment.
Furthermore,
Laparoscopic
Approach
Cervical
Cancer
trial
significantly
impacted
perceptions
revealing
higher
recurrence
rates
inferior
overall
survival
minimally
radical
hysterectomy
(MIS‐RH)
compared
abdominal
hysterectomy.
Subsequent
studies
confirmed
these
findings,
raising
questions
about
suitability
MIS‐RH,
centers
with
limited
experience.
Key
issues
affecting
MIS
outcomes
include
surgical
expertise
tumor
spillage
prevention.
As
landscape
cervical
cancer
evolves,
integration
radiotherapy,
chemotherapy,
immune
therapies
challenged
traditional
reliance
on
monotherapy.
There
also
exists
ongoing
debate
over
optimal
primary
salvage
refine
techniques
explore
their
preserving
fertility
managing
residual
disease
post‐chemoradiotherapy.
For
ensuring
as
viable
option,
it
is
continuously
necessary
accumulating
real‐world
data
reassessing
strategies
balance
efficacy,
safety,
patient
preferences.
Language: Английский
Tumor immunology and immunotherapy for endometrial cancer
Expert Opinion on Investigational Drugs,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 12
Published: Feb. 6, 2025
Recent
clinical
trials
show
the
efficacy
of
immune
checkpoint
inhibitors
(ICIs)
or
a
combination
ICI
and
poly
(ADP-ribose)
polymerase
(PARP)
for
advanced
recurrent
endometrial
cancer.
However,
basis
such
treatment
effects
remains
unclear,
hindering
advancement
personalized
therapy.
This
review
includes
detailed
interpretation
subgroup
analysis
data
from
phase
III
cancer
evaluating
chemotherapy
plus
ICIs
(NRG-GY018,
RUBY,
AtTEnd,
KEYNOTE-B21)
with/without
olaparib
(DUO-E).
We
focused
on
relationship
between
obesity,
effect
PARP
inhibitors,
tumor
immunity
in
cancer,
searched
relevant
literature
published
2000
to
2024
PubMed,
conducted
narrative
review.
Chemotherapy
is
appropriate
dMMR.
inhibitor
may
be
TP53abn
type
serous
carcinoma
because
enhances
by
activating
cyclic
guanosine
monophosphate-adenosine
monophosphate
synthase
(cGAS)-stimulator
interferon
genes
(STING)
pathway.
Obese
patients
benefit
more
ICIs,
this
appears
cause
variation
regions/countries.
Administration
measurable
disease
important
increase
ICIs.
Diet
exercise
also
factors.
Language: Английский
Identification of ovarian high-grade endometrioid-type tumors through multi-omics analysis: JGOG3025-TR2 study
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: April 13, 2024
Abstract
Objective
There
is
considerable
interobserver
variability
in
the
differential
diagnosis
between
ovarian
high-grade
endometrioid
carcinoma
(HGEC)
and
serous
(HGSC)
due
to
their
histopathological
similarities.
While
association
homologous
recombination
deficiency
(HRD)
platinum
sensitivity
PARP
inhibitors
well
established
HGSC,
molecular
characteristics
of
HGEC
remain
unclear.
Methods
Fresh-frozen
tissue
samples
from
15
HGECs
274
HGSCs
morphologically
diagnosed
by
central
pathology
review
Japanese
Gynecological
Oncology
Group
(JGOG)
were
subjected
targeted
DNA
sequencing,
RNA
methylation
array,
SNP
array
analysis.
Tumors
classified
unsupervised
clustering
based
on
copy
number
variation
signatures.
External
datasets
including
555
287
endometrial
carcinomas
The
Cancer
Genome
Atlas
project
(TCGA-OV
TCGA-UCEC)
also
analyzed.
Results
Four
distinct
groups
identified
JGOG
cohort.
C1
(n=41)
showed
CCNE1
amplification
poor
survival.
C2
(n=160)
C3
(n=59)
a
high
frequency
BRCA
alterations
with
moderate
low
aneuploidy,
respectively.
C4
(n=22)
was
characterized
favorable
survival,
higher
HGEC,
absence
both
alteration
amplification,
levels
HRD
score,
ploidy,
intra-tumoral
heterogeneity,
cell
proliferation
rate,
WT1
gene
expression.
Additionally,
exhibited
normal
endometrium-like
profile
defined
as
an
“HGEC-type”
tumor.
HGEC-type
tumors
TCGA-OV
TCGA-UCEC.
Conclusions
Ovarian
exhibit
non-HRD
status,
prognosis,
differentiation,
may
comprise
subset
HGSC.
Language: Английский
A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer
International Cancer Conference Journal,
Journal Year:
2024,
Volume and Issue:
13(4), P. 525 - 531
Published: Sept. 17, 2024
Language: Английский
Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan
Journal of Gynecologic Oncology,
Journal Year:
2024,
Volume and Issue:
36
Published: Nov. 20, 2024
This
cross-sectional
study
aimed
to
understand
the
actual
situation
of
shared
decision-making
(SDM)
and
identify
challenges
implementing
SDM
among
Japanese
gynecologic
cancer
patients
healthcare
professionals
(HCPs).
Language: Английский
Carcinogenesis and epidemiology of cervical cancer: The hallmark of human papillomavirus‐associated cancer
Osamu Kobayashi,
No information about this author
Saki Kamata,
No information about this author
Yuki Okuma
No information about this author
et al.
Journal of Obstetrics and Gynaecology Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 5, 2024
Abstract
Cervical
cancer
affects
women
worldwide
and
is
the
most
common
human
papillomavirus
(HPV)‐associated
cancer.
Carcinogenesis
caused
by
HPV
results
in
specific
behavior
because
of
underlying
viral
infection.
The
mechanism
timing
transformation
from
infection
to
cells
have
been
elucidated
detail.
Treatments
for
this
are
based
on
its
characteristics
being
implemented.
Moreover,
widespread
transmitted
through
sexual
activity.
Although
vaccination
effective
strategy
preventing
cervical
cancer,
it
not
feasible
vaccinate
entire
population
especially
low‐
middle‐income
countries.
In
order
consider
next
step
vaccination,
we
need
understand
carcinogenesis
Additionally,
treatment
aimed
at
preservation
reproductive
function
patients
with
often
required,
as
cervix
a
organ
disease
more
prevalent
adolescent
young
adult
generation.
Thus,
there
still
many
challenges
diagnosis,
treatment,
prevention
Language: Английский